Sequencing Human Genome has identified 24,000 genes in our genome. Out of which six- thousand genes are mutated and are responsible for causing six thousand different diseases including old age diseases such as Alzheimer, Cardiovascular Disease and Cancers. Of all the cancers, brain cancer is most difficult to treat. The drug delivery methods require to transport active drugs components from the injection site to the target site. To treat all mental illnesses including brain cancer, the greatest challenge for most scientists is to deliver drug across the natural filter called, the Blood Brain Barrier (BBB). Besides addictive narcotics, most drugs are filtered out by BBB. Of all the cancers, developing drugs to treat brain cancer presents the greatest challenge. Glioblastoma is the solid, aggressive and the deadliest form of brain cancer. Once diagnosed, most patients die within fourteen months of their diagnosis. By making AZQ (US Patent 4,233,215), I have demonstrated, a novel drug delivery method by attaching Quinone, a non-addictive, non-toxic chemical as a carrier, I could deliver prodrug moieties like Aziridines and Carbamates across BBB to attack Glioblastoma, the brain tumor. Once it crosses the BBB, AZQ, a prodrug, remains inactive at natural pH, but it is activated by the growing brain tumor. To grow, the Glioblastoma uses glucose as a source of energy. Glucose is broken down to produce Lactic Acid. In the acidic media, the prodrug moieties Aziridines and Carbamates are activated producing the most powerful Carbonium ions which attack the tumor DNA shutting off the genes. Instead of growing, the Glioblastoma starts shrinking. By making AZQ and using Quinone as a drug delivery chemical across BBB, I opened the path to attack all other mental illnesses such as Epilepsy, Schizophrenia, Bipolar disorder, Depression, Anxiety disorders, Paranoia, Psychosis and Aggression. In future, male and female hormones could be used to deliver active drug components such as aziridines and carbamates to attack Breast and Prostate cancers.
Published in | International Journal of Genetics and Genomics (Volume 10, Issue 3) |
DOI | 10.11648/j.ijgg.20221003.12 |
Page(s) | 64-78 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Glioblastoma, Aziridines, Carbamate, Quinone, Blood Brain Barrier, AZQ
[1] | Watson, J. D., & Crick, F. H. C. A structure for deoxyribose nucleic acid. Nature 171, 737–738 (1953). |
[2] | Nature, 409, 934-941, 2001 The Impact of Sequencing Human Genome on Genomic Food... https://www.sciencepublishinggroup.com › paperinfo Apr 16, 2021 — Genome Sequencing, Nature, 409,934-941, 2001. [3]. Genetics, Nature, 409, 660-921, 2001. [4]. Genomics, Nature, 431, 931-945, 2004. |
[3] | Nature, 409, 660-921, 2001 Initial sequencing and analysis of the human genome - PubMed https://pubmed.ncbi.nlm.nih.gov ›... by ES Lander · 2001 · Cited by 27842 — Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15; 409 (6822): 860-921. doi: 10.1038/35057062. Authors. E S Lander, L M Linton,... Missing: 660-921, | Must include: 660-921, |
[4] | Nature, 431, 931-945, 2004 Sequencing of Human Genome, Scholarly articles for Nature, 431, 931-945, 2004 End of the beginning - Stein - Cited by 430 Finishing the euchromatic sequence of the human … - International Human … - Cited by 4641 TerraGenome: a consortium for the sequencing of a … - Vogel - Cited by 261. |
[5] | Nature, 438, 803-810, 2005 Genome sequence, comparative analysis and haplotype... https://pubmed.ncbi.nlm.nih.gov ›...by K Lindblad-Toh · 2005 · Cited by 2769 — Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005 Dec 8; 438 (7069): 803-19. doi: 10.1038/nature04338. Missing: 803-810, | Must include: 803-810. |
[6] | Nature, 550, 345-353, 2017 DNA sequencing at 40: past, present and future - PubMed https://pubmed.ncbi.nlm.nih.gov ...by J Shendure · 2017 · Cited by 786 — DNA sequencing at 40: past, present and future. Nature. 2017 Oct 19; 550 (7676): 345-353. doi: 10.1038/nature24286. Epub 2017 Oct 11. |
[7] | Chlorambucil - CancerConnect News". CancerConnect News. Retrieved 2015-12-21. Chlorambucil". Journal of the American Chemical Society. 136 (16): 5860–5863 Chlorambucil) Drug Information: Description, User Reviews, Drug Side Effects, Interactions – Prescribing Information at RxList". |
[8] | Ross. W. C. J, “The Chemistry of Cytotoxic Alkylating Agents” In Advances in Cancer Research by Greenstein, J. P., and Haddow, A., Academic Press, Inc., New York,, 397-449, (1953). |
[9] | Ross, W. C. J., “Biological Alkylating Agents” Butterworth, London, 1962. |
[10] | Ross, W. C. J., Journal of Chemical Society, 183, 1949. |
[11] | Ross, W. C. J., J. Chem. Soc., 2257 (1950). |
[12] | Ross, W. C. J., Mitchley, B. C. V., Ann. Rep. Brit. Empire Cancer Campn, 42, 70 (1964). |
[13] | Melphalan Lancet 370 (9594): 1209–18. |
[14] | L. M. Cobb, T. A. Connors, L. A. Elson, A. H. Khan, B. C. V. Mitchley, W. C. J. Ross and M. E. Whisson, BIOCHEMICAL PHARMACOLOGY, col. 18, pp. 1519-1527 (1969) "2,4-Dinitro-5-Ethyleneiminobenzamide (CB 1954): A Potent and Selective Inhibitor of the Growth of the Walker Carcinoma 256". |
[15] | A. H. Khan and W. C. J. Ross, CHEM.-BIOL INTERACTIONS, vol 1, pp. 27-47 (1969/70) "Tumour-Growth Inhibitory Nitrophenylaziridines and related compounds: Structure-Activity Relationships" PART I. |
[16] | A. H. Khan and W. C. J. Ross, CHEM.-BIOL INTERACTIONS, vol 4, pp. 11-22 (1971/72) "Tumour-Growth Inhibitory Nitrophenylaziridines and related compounds: Structure-Activity Relationships" PART II. |
[17] | A. Hameed Khan and John Driscoll, JOURNAL OF MEDICINAL CHEMISTRY, vol. 19, No. 2, pp. 313-317 (1976) "Potential Central Nervous System Antitumor Agents: Aziridinylbenzoquinones. PART I. |
[18] | Ed Chou, A. Hameed Khan and John Driscoll, JOURNAL OF MEDICINAL CHEMISTRY, vol. 19, pp. 1302 (1976) "Potential Central Nervous System Antitumor Agents: Aziridinylbenzoquinones. PART II. |
[19] | "Aziridine Quinone: Anti-transplanted Tumor Agents". UNITES STATES PATENT # 4,146,622, & 4,233,215 (March 27, 1979) Investors: John S. Driscoll; A. Hameed Khan; Feng-e-Chou, NIH, Maryland, USA Additional Information is available at Facebook.com/hameed.khan 7773. |
[20] | The Impact of Diagnostic MRI on the Early Detection of Lethal Genes in Human Genome and to Develop Genomic Medicine to Treat Brain Cancers. J Med - Clin Res & Rev. 2021; 5 (6): 1-9. |
[21] | 2020 – A chapter was Published in the Book entitled, Prevention, Detection and Management of Oral Cancer: Chapter entitled, “The Impact of Sequencing Human Genome on Drug Design to Treat Oral Cancer: Published in the IntechOpen. |
[22] | 2018 – A chapter was Published in the book entitled, “Development of Oral Cancer – Risk Factors and Prevention Strategies”: Published by Springer & Edited by Ala-Eddin Al Moustafa. |
[23] | Journal of Medical - Clinical Research & Reviews ISSN 2639-944X J Med - Clin Res & Rev; 2021 Volume 5 | Issue 6 | 1 of 9 The Impact of Diagnostic MRI on the Early Detection of Lethal Genes in Human Genome and to Develop Genomic Medicine to Treat Brain Cancers. |
[24] | e-Book, “The Impact of Sequencing Human Genome on Genomic Medicine and the Discovery of AZQ (US Patent 4,146,622) Specifically Designed to shut off genes that cause Brain Cancer.” |
[25] | The Rational Drug Design to Treat Cancers Abdul Hameed Khan. |
[26] | The Impact of Sequencing Human Genome on Genomic Food & Medicine. |
[27] | The Impact of Sequencing Genomes on The Human Longevity Project. |
[28] | Hameed AK. The Impact of Diagnostic MRI on the Early Detection of Lethal Genes in Human Genome and to Develop Genomic Medicine to Treat Brain Cancers. J Med - Clin Res & Rev. 2021; 5 (6): 1-9. |
[29] | Khan H. The Impact of Sequencing Genomes on The Human Longevity Project. J Med - Clin Res & Rev. 2021; 5 (7): 1-12. |
[30] | Hameed Khan. The Impact of Sequencing Human Genome on Genomic Food & Medicine. International Journal of Genetics and Genomics. Vol. 9, No. 1, 2021, pp. 6-19. doi: 10.11648/j.ijgg.20210901.12. |
[31] | ADVANCES IN MEDICINE AND BIOLOGY, VOLUME 180, The Impact of Sequencing Human Genome on Genomic Medicine and the Discovery of AZQ (US Patent 4,146,622) Specifically Designed to Shut off Genes That Cause Brain Cancer Hameed Khan. |
[32] | Chapter 5 Drug Design - Novel Advances in the Omics Field and Applications Edited by Arli Aditya Parikesit “The Rational Drug Design to Treat Cancers.” Page, 95-115, 2021. |
[33] | Abbreviated Key Title: EAS J Biotechnol Genet ISSN: 2663-189X (Print) & ISSN: 2663-7286 (Online) Published By East African Scholars Publisher, Kenya Volume-3 | Issue-3 | May-Jun-2021 | DOI: 10.36349/easjbg.2021.v03i03.002. |
[34] | The Impact of Genomic Science on Society & the Discovery of AZQ (US Patents 4,146,622 and 4,233,215) rationally Design to attack Glioblastoma, The Brain Tumor. |
[35] | Genomic Medicine: Using Genetic Make-up of the Human Genome, Genomic Medicine: Using Genetic Make-up of the Human Genome, AZQ was Designed to Treat Glioblastoma, the Brain Tumor, Crimson Publishers. |
[36] | Journal of Cancer Research Reviews & Reports- The Impact of Sequencing Human Genome on Cancer Chemotherapy. |
[37] | A Hameed Khan. The Impact of Sequencing Genomes on the Understanding of the Origin of Life on Earth. Biomed J Sci & Tech Res 40 (2)-2021. BJSTR. MS.ID.006416. |
[38] | A. Hameed Khan. (2022). The Impact of Sequencing Human Genome on the Genetically Engineered Life. J. Cancer Research and Cellular Therapeutics. 6 (1); DOI: 10.31579/2640-1053/102. |
APA Style
Hameed Khan. (2022). The Impact of Sequencing Human Genome on Novel Drug Delivery Method to Treat Cancers. International Journal of Genetics and Genomics, 10(3), 64-78. https://doi.org/10.11648/j.ijgg.20221003.12
ACS Style
Hameed Khan. The Impact of Sequencing Human Genome on Novel Drug Delivery Method to Treat Cancers. Int. J. Genet. Genomics 2022, 10(3), 64-78. doi: 10.11648/j.ijgg.20221003.12
@article{10.11648/j.ijgg.20221003.12, author = {Hameed Khan}, title = {The Impact of Sequencing Human Genome on Novel Drug Delivery Method to Treat Cancers}, journal = {International Journal of Genetics and Genomics}, volume = {10}, number = {3}, pages = {64-78}, doi = {10.11648/j.ijgg.20221003.12}, url = {https://doi.org/10.11648/j.ijgg.20221003.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijgg.20221003.12}, abstract = {Sequencing Human Genome has identified 24,000 genes in our genome. Out of which six- thousand genes are mutated and are responsible for causing six thousand different diseases including old age diseases such as Alzheimer, Cardiovascular Disease and Cancers. Of all the cancers, brain cancer is most difficult to treat. The drug delivery methods require to transport active drugs components from the injection site to the target site. To treat all mental illnesses including brain cancer, the greatest challenge for most scientists is to deliver drug across the natural filter called, the Blood Brain Barrier (BBB). Besides addictive narcotics, most drugs are filtered out by BBB. Of all the cancers, developing drugs to treat brain cancer presents the greatest challenge. Glioblastoma is the solid, aggressive and the deadliest form of brain cancer. Once diagnosed, most patients die within fourteen months of their diagnosis. By making AZQ (US Patent 4,233,215), I have demonstrated, a novel drug delivery method by attaching Quinone, a non-addictive, non-toxic chemical as a carrier, I could deliver prodrug moieties like Aziridines and Carbamates across BBB to attack Glioblastoma, the brain tumor. Once it crosses the BBB, AZQ, a prodrug, remains inactive at natural pH, but it is activated by the growing brain tumor. To grow, the Glioblastoma uses glucose as a source of energy. Glucose is broken down to produce Lactic Acid. In the acidic media, the prodrug moieties Aziridines and Carbamates are activated producing the most powerful Carbonium ions which attack the tumor DNA shutting off the genes. Instead of growing, the Glioblastoma starts shrinking. By making AZQ and using Quinone as a drug delivery chemical across BBB, I opened the path to attack all other mental illnesses such as Epilepsy, Schizophrenia, Bipolar disorder, Depression, Anxiety disorders, Paranoia, Psychosis and Aggression. In future, male and female hormones could be used to deliver active drug components such as aziridines and carbamates to attack Breast and Prostate cancers.}, year = {2022} }
TY - JOUR T1 - The Impact of Sequencing Human Genome on Novel Drug Delivery Method to Treat Cancers AU - Hameed Khan Y1 - 2022/07/29 PY - 2022 N1 - https://doi.org/10.11648/j.ijgg.20221003.12 DO - 10.11648/j.ijgg.20221003.12 T2 - International Journal of Genetics and Genomics JF - International Journal of Genetics and Genomics JO - International Journal of Genetics and Genomics SP - 64 EP - 78 PB - Science Publishing Group SN - 2376-7359 UR - https://doi.org/10.11648/j.ijgg.20221003.12 AB - Sequencing Human Genome has identified 24,000 genes in our genome. Out of which six- thousand genes are mutated and are responsible for causing six thousand different diseases including old age diseases such as Alzheimer, Cardiovascular Disease and Cancers. Of all the cancers, brain cancer is most difficult to treat. The drug delivery methods require to transport active drugs components from the injection site to the target site. To treat all mental illnesses including brain cancer, the greatest challenge for most scientists is to deliver drug across the natural filter called, the Blood Brain Barrier (BBB). Besides addictive narcotics, most drugs are filtered out by BBB. Of all the cancers, developing drugs to treat brain cancer presents the greatest challenge. Glioblastoma is the solid, aggressive and the deadliest form of brain cancer. Once diagnosed, most patients die within fourteen months of their diagnosis. By making AZQ (US Patent 4,233,215), I have demonstrated, a novel drug delivery method by attaching Quinone, a non-addictive, non-toxic chemical as a carrier, I could deliver prodrug moieties like Aziridines and Carbamates across BBB to attack Glioblastoma, the brain tumor. Once it crosses the BBB, AZQ, a prodrug, remains inactive at natural pH, but it is activated by the growing brain tumor. To grow, the Glioblastoma uses glucose as a source of energy. Glucose is broken down to produce Lactic Acid. In the acidic media, the prodrug moieties Aziridines and Carbamates are activated producing the most powerful Carbonium ions which attack the tumor DNA shutting off the genes. Instead of growing, the Glioblastoma starts shrinking. By making AZQ and using Quinone as a drug delivery chemical across BBB, I opened the path to attack all other mental illnesses such as Epilepsy, Schizophrenia, Bipolar disorder, Depression, Anxiety disorders, Paranoia, Psychosis and Aggression. In future, male and female hormones could be used to deliver active drug components such as aziridines and carbamates to attack Breast and Prostate cancers. VL - 10 IS - 3 ER -